AbbVie reported first-quarter 2026 revenue of $15 billion, surpassing analyst expectations of $14.72 billion, driven by strong growth in its immunology and neuroscience portfolios. Immunology sales rose 16.4%, led by Skyrizi and Rinvoq, while neuroscience sales increased 26%, including gains from Vraylar and Botox Therapeutics. Despite a slight decline in oncology sales, the company raised its full-year adjusted earnings guidance to $14.08-$14.28 per share, reflecting confidence in continued momentum. CEO Robert Michael highlighted the strong performance across key segments as a positive start to the year.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
